Abstract
Background:
Multiple myeloma (MM) is typically diagnosed based on systemic symptoms such as anemia or fatigue, or through imaging findings of bone lytic lesions. Neurologic manifestations as the initial presentation are rare. In this case, we report a patient diagnosed with MM after presenting with severe, unilateral vision loss.
Methods:
A 67-year-old woman presented with a 5-day history of painless vision loss in her left eye. Her visual acuity was severely reduced to light perception, yet both the optic disc and retinal vessels appeared normal upon examination. Blood tests revealed no significant abnormalities except for anemia. Magnetic resonance imaging (MRI) revealed enhancement of the left optic nerve sheath, and bone marrow biopsy confirmed MM. High-dose steroid and subsequent chemotherapy led to significant visual improvement.
Conclusions:
Unilateral optic perineuritis can be the first manifestation of MM, potentially caused by immune-mediated mechanisms or direct tumor cell infiltration near the optic nerve. Steroid not only contributed to symptom improvement but also may have played a role in partial remission of MM.
Introduction
Multiple myeloma (MM) is a hematologic malignancy marked by abnormal plasma cell proliferation, commonly presenting with bone lesions, kidney injury, anemia, or hypercalcemia (). While over 70% of cases are diagnosed through anemia or bone lytic lesions, only about 3% present as extramedullary disease, including nervous system involvement ().
There are few reports with optic nerve involvement, and those were after the diagnosis of MM (). The occurrence of acute ophthalmological symptoms as the first clue leading to a diagnosis of MM is exceedingly rare. Herein, we report an unusual case in which MM was diagnosed based on acute unilateral vision loss due to optic perineuritis.
Case description and diagnostic assessment
A 67-year-old woman presented with a 5-day history of painless vision loss in her left eye. Her medical history included angina pectoris and coronary artery bypass surgery. Corrected visual acuity prior to onset had been 20/40 in both eyes. On neurological examination, there were no accompanying sensory or motor deficits. Her visual acuity was limited to light perception in the left eye and 20/40 in the right. Fundus photography (Figure 1A), fluorescein angiography (Figures 1D–F), and optical coherence tomography were unremarkable. The Humphrey visual field test revealed a mean deviation (MD) of −29.52 dB (Figure 2A), indicating severe visual field loss. Orbital magnetic resonance imaging (MRI) revealed enhancement of the left optic nerve sheath without nerve involvement or compressive lesions (Figures 1B,C). Other meningeal or parenchymal abnormalities were not noted.
Figure 1
Figure 2
Laboratory evaluation showed marked anemia (hemoglobin, 6.8 g/dL). Fluorescent antinuclear antibodies; anti-Smith, anti-Ro, and anti-La; anti-nuclear and anti-dsDNA antibodies; and paraneoplastic antibodies including anti-Hu, anti-Yo, anti-Ri, anti-amphiphysin, anti-CV2, anti-Ma, anti-SOX1, and anti-recoverin were negative; angiotensin converting enzymes were within normal limit. The anti-aquaporin 4 IgG antibody and MOG antibody were also negative. Erythrocyte sedimentation rate was 88 mm/h (normal, 0–15) and C-reactive protein was 2.5 mg/dL (normal, 0–0.5). Cerebrospinal fluid analysis showed mild pleocytosis (14 cells/μL) and elevated protein (168.1 mg/dL) but no malignant cells or oligoclonal bands.
Chest computed tomography (CT) revealed post-status median sternotomy without any sarcoidosis. Abdominal CT revealed mural thickening of the transverse colon, with biopsy confirming light chain amyloidosis. Serum and urine protein electrophoresis showed IgG-kappa monoclonal protein. Bone marrow biopsy revealed >60% plasma cells demonstrated by CD138 immunohistochemical staining, confirming MM (Figures 1D–F). According to the Revised International Staging System and International Myeloma Working Group, the patient was also categorized as stage II, moderate stage, with a standard-risk profile.
Discussion
In elderly patients with vascular risk factor, the most clinically significant consideration for painless severe visual loss is an ischemic lesion affecting the retina or optic nerve (). Since arterial anterior ischemic optic neuritis (AION) is accompanied by pain, it can be excluded, but non-arterial AION can also commonly occur in patients such as ours. However, our patient did not exhibit any abnormalities in the retinal vessels or the optic disc, nor were there any findings suggestive of inflammation, making the diagnosis particularly challenging. Nevertheless, the thorough systemic evaluation from unusual optic perineuritis led to the timely diagnosis of a serious underlying malignancy. This case is unique in that unilateral optic perineuritis was the first and sole manifestation of MM. Although bilateral optic nerve involvement has been reported in MM, it usually occurs later in the disease course or as a manifestation of CNS spread (). To the best of our knowledge, this is the first reported case in which painless unilateral optic nerve involvement led to the diagnosis of MM.
Potential mechanisms include direct neoplastic infiltration, immune-associated inflammation, or perineural amyloid deposition (). Leptomeningeal seeding typically presents with headache, bilateral involvement, and dural thickening, allowing easier differentiation from other optic nerve disorders (). However, painless unilateral optic perineuritis as observed in our case represents an atypical clinical presentation (). When observing such atypical features, it may be considered that the inflammation is caused by immune-associated rather than idiopathic perineuritis, which is mainly accompanied by pain ().
Steroids are a cornerstone treatment in both idiopathic perineuritis and MM regimens (, ). In our case, the marked improvement in visual function following steroid therapy may suggest immune-mediated pathology, but this also makes it difficult to exclude the possibility of direct involvement of MM (). Even if it is important to rule out the possibility of a very rare disease occurring spontaneously, a biopsy is difficult to perform on the optic nerve because it may cause irreversible damage. Further analysis of similar cases in the future may be necessary to better understand this rare presentation.
Patient perspective
The patient received intravenous methylprednisolone (1 g/day for 5 days), which resulted in rapid visual improvement. Her visual acuity recovered to 20/40 bilaterally, and visual field MD improved to −10.13 dB (Figure 2B). Following chemotherapy, the VRd regimen (bortezomib, lenalidomide, and dexamethasone) was initiated and continued for over 10 months, during which her vision remained stable.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
This study followed the tenets of the Declaration of Helsinki and was performed according to the guidelines of the Institutional Review Board of Pusan National University Hospital (2408-019-142). Written informed consent was obtained from the patient for publication of this case report and any accompanying images. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
EJ: Writing – original draft. J-HC: Writing – original draft, Supervision. K-DC: Writing – original draft, Conceptualization. S-YC: Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by a clinical research grant from the Pusan National University Hospital in 2024 and a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (RS-2024-00347906).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
CowanAJGreenDJKwokMLeeSCoffeyDGHolmbergLAet al. Diagnosis and management of multiple myeloma: A review. JAMA. (2022) 327:464–77. doi: 10.1001/jama.2022.0003
2
ThomsonACNakawahMORaviskanthanSMortensenPWLeeAG. Neuro-ophthalmic presentation of myelomatous meningitis. J Neuroophthalmol. (2022) 42:e417–9. doi: 10.1097/WNO.0000000000001287
3
Roskal-WalekJRuzikAKubisNTeperMWesolowskiMWujecZet al. Therapeutic strategies for retinal artery occlusion-A literature review. J Clin Med 13. (2024) 13(2):6813. doi: 10.3390/jcm13226813
4
YeungSNPatonKEDorovini-ZisKChewJBWhiteVA. Histopathologic features of multiple myeloma involving the optic nerves. J Neuroophthalmol. (2008) 28:12–6. doi: 10.1097/WNO.0b013e3181675457
5
YilmazSGTureGZenginMOTalayEMenS. Optic nerve and dura mater involvement as the first sign of multiple myeloma. Eur J Ophthalmol. (2015) 25:77–9. doi: 10.5301/ejo.5000489
6
SaitakisGChwaliszBK. Optic perineuritis. Curr Opin Ophthalmol. (2022) 33:519–24. doi: 10.1097/ICU.0000000000000900
7
van de DonkNPawlynCYongKL. Multiple myeloma. Lancet. (2021) 397:410–27. doi: 10.1016/S0140-6736(21)00135-5
Summary
Keywords
multiple myeloma, optic neuritis, optic perineuritis, visual loss, optic nerve
Citation
Jung E, Choi J-H, Choi K-D and Choi S-Y (2025) Case Report: Unilateral optic perineuritis as the initial presentation of multiple myeloma. Front. Ophthalmol. 5:1616532. doi: 10.3389/fopht.2025.1616532
Received
08 May 2025
Accepted
09 October 2025
Published
06 November 2025
Volume
5 - 2025
Edited by
Andrew Lee, Houston Methodist Hospital, United States
Reviewed by
Indra Tri Mahayana, Gadjah Mada University, Indonesia
Aditya Barigali, Vardhaman Superspecialty Eye Hospital, India
Updates
Copyright
© 2025 Jung, Choi, Choi and Choi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Seo-Young Choi, csy035.12@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.